Anbio Biotechnology and Oncocyte Compared in Financial Analysis

Comparing the manufacturing companies Anbio Biotechnology and Oncocyte to determine which is the better stock

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN) are both manufacturing companies, but a financial analysis shows Anbio Biotechnology has higher revenue and earnings than Oncocyte. The analysis compares the two companies on factors like valuation, profitability, dividends, analyst recommendations, risk, earnings, and institutional ownership.

Why it matters

This analysis provides investors with a comprehensive comparison of two publicly traded manufacturing companies in the biotech industry, helping them make informed decisions about which stock may be the better investment option.

The details

The analysis found that Anbio Biotechnology has higher revenue and earnings than Oncocyte. Anbio also beats Oncocyte on 6 out of 10 factors compared, including net margins, return on equity, and return on assets. However, analysts believe Oncocyte has more potential upside, with a consensus price target indicating 120% potential upside compared to Anbio.

  • The analysis is based on the most recent financial data available as of March 8, 2026.

The players

Oncocyte Corporation

A molecular diagnostics company that researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer.

Anbio Biotechnology

A company dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products, with a focus on transforming the diagnostics landscape through personalized and decentralized solutions.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the competitive landscape in the biotech manufacturing industry, where companies like Oncocyte and Anbio Biotechnology are vying for investor attention. While Anbio Biotechnology may have stronger financial metrics, Oncocyte's potential upside as perceived by analysts suggests the market sees greater growth opportunities for the company.